Exploring the Evidence for Broad-Spectrum Effectiveness of Perampanel: A Systematic Review of Clinical Data in Generalised Seizures.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
22
05
2021
pubmed:
8
7
2021
medline:
4
2
2022
entrez:
7
7
2021
Statut:
ppublish
Résumé
The effectiveness of adjunctive perampanel has not been systematically assessed in seizure types other than its approved indications of focal seizures and primary generalised tonic-clonic seizures (PGTCS) in idiopathic generalised epilepsies (IGEs). We aimed to identify and review available evidence on outcomes with perampanel in generalised seizures and epilepsies to examine its potential as a broad-spectrum anti-seizure medication. Bibliographic databases of publications, clinical trials, and conference abstracts were searched up to August 2020 to identify studies reporting seizure or safety outcomes in patients of any age, with any type of epilepsy-associated generalised seizures treated with perampanel. Data extracted from selected records were tabulated by seizure type and syndrome, and analysed qualitatively (PROSPERO protocol CRD42020201564). Ninety-one reports met inclusion criteria and were selected: 15 reports of 1 randomised controlled trial (RCT), 8 reports of 4 non-randomised interventional studies, 37 reports of observational studies, 21 case reports and 10 systematic reviews and meta-analyses. Extracted data included 359 patients with PGTCS of any aetiology, 251 with myoclonic seizures, 112 with absence seizures, 50 with tonic seizures and 32 children with epileptic spasms. The most commonly reported epilepsy type was IGE (N = 378) and the most common syndromes were juvenile myoclonic epilepsy (N = 92), progressive myoclonic epilepsies (N = 59) and absence epilepsies (N = 43). The RCT provided Class I evidence of the efficacy and tolerability of adjunctive perampanel for PGTCS in patients aged ≥ 12 years with IGE. Data from other studies provides weaker (observational) evidence of its effectiveness in multiple generalised seizure types, including myoclonic, absence and tonic seizures. There were no patterns suggesting seizure worsening or aggravation in any seizure or epilepsy type. The identified studies suggest the potential of perampanel as a broad-spectrum antiseizure medication. Much of the available data, however, come from non-randomised, non-controlled studies and are open to high risk of bias. Further studies are warranted to provide more robust evidence.
Sections du résumé
BACKGROUND
The effectiveness of adjunctive perampanel has not been systematically assessed in seizure types other than its approved indications of focal seizures and primary generalised tonic-clonic seizures (PGTCS) in idiopathic generalised epilepsies (IGEs).
OBJECTIVE
We aimed to identify and review available evidence on outcomes with perampanel in generalised seizures and epilepsies to examine its potential as a broad-spectrum anti-seizure medication.
METHODS
Bibliographic databases of publications, clinical trials, and conference abstracts were searched up to August 2020 to identify studies reporting seizure or safety outcomes in patients of any age, with any type of epilepsy-associated generalised seizures treated with perampanel. Data extracted from selected records were tabulated by seizure type and syndrome, and analysed qualitatively (PROSPERO protocol CRD42020201564).
RESULTS
Ninety-one reports met inclusion criteria and were selected: 15 reports of 1 randomised controlled trial (RCT), 8 reports of 4 non-randomised interventional studies, 37 reports of observational studies, 21 case reports and 10 systematic reviews and meta-analyses. Extracted data included 359 patients with PGTCS of any aetiology, 251 with myoclonic seizures, 112 with absence seizures, 50 with tonic seizures and 32 children with epileptic spasms. The most commonly reported epilepsy type was IGE (N = 378) and the most common syndromes were juvenile myoclonic epilepsy (N = 92), progressive myoclonic epilepsies (N = 59) and absence epilepsies (N = 43). The RCT provided Class I evidence of the efficacy and tolerability of adjunctive perampanel for PGTCS in patients aged ≥ 12 years with IGE. Data from other studies provides weaker (observational) evidence of its effectiveness in multiple generalised seizure types, including myoclonic, absence and tonic seizures. There were no patterns suggesting seizure worsening or aggravation in any seizure or epilepsy type.
CONCLUSIONS
The identified studies suggest the potential of perampanel as a broad-spectrum antiseizure medication. Much of the available data, however, come from non-randomised, non-controlled studies and are open to high risk of bias. Further studies are warranted to provide more robust evidence.
Identifiants
pubmed: 34232492
doi: 10.1007/s40263-021-00831-y
pii: 10.1007/s40263-021-00831-y
pmc: PMC8354889
doi:
Substances chimiques
Anticonvulsants
0
Nitriles
0
Pyridones
0
perampanel
H821664NPK
Types de publication
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
821-837Informations de copyright
© 2021. The Author(s).
Références
Eur Neurol. 2014;72(3-4):213-6
pubmed: 25227593
eNeurologicalSci. 2019 Nov 18;17:100215
pubmed: 31799456
Neurology. 2014 Dec 2;83(23):2188
pubmed: 25361780
Epilepsy Behav Case Rep. 2018 Mar 12;10:32-34
pubmed: 29977792
Epilepsia. 2018 Sep;59(9):1740-1752
pubmed: 30062784
Case Rep Psychiatry. 2014;2014:409209
pubmed: 25580340
Clin Neurophysiol. 2021 May;132(5):1049-1056
pubmed: 33743300
Acta Neurol Scand. 2018 Aug;138(2):122-129
pubmed: 29573400
Seizure. 2017 Nov;52:63-70
pubmed: 28992560
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Neuropediatrics. 2015 Apr;46(2):110-6
pubmed: 25730374
Epilepsia. 2020 Jan;61(1):125-137
pubmed: 31912493
Epilepsia. 2013 Aug;54(8):1481-9
pubmed: 23663001
Case Rep Neurol. 2017 Dec 11;9(3):284-288
pubmed: 29422850
Epilepsy Behav. 2019 May;94:82-86
pubmed: 30897534
Epilepsy Behav Case Rep. 2019 Jan 11;11:67-69
pubmed: 30723672
Epilepsy Behav Case Rep. 2014 Sep 29;2:164-6
pubmed: 25667898
Epilepsy Behav Case Rep. 2017 May 26;8:44-46
pubmed: 28856097
Neurology. 2015 Sep 15;85(11):950-7
pubmed: 26296511
Epilepsy Res. 2020 Sep;165:106378
pubmed: 32622260
Epilepsia. 2017 Apr;58(4):522-530
pubmed: 28276060
Epilepsy Res. 2019 Oct;156:106191
pubmed: 31446282
Epilepsy Behav Case Rep. 2013 Aug 16;1:118-21
pubmed: 25667843
An Pediatr (Engl Ed). 2019 Nov;91(5):346-348
pubmed: 30797704
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Seizure. 2019 Dec;73:75-78
pubmed: 31759296
J Clin Neurol. 2020 Jan;16(1):53-59
pubmed: 31942758
J Child Neurol. 2019 Apr;34(5):284-294
pubmed: 30739576
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Pediatr Neurol. 2020 Aug;109:91-93
pubmed: 32299749
J Neurol Sci. 2018 Jul 15;390:67-74
pubmed: 29801910
Seizure. 2020 Aug;80:115-123
pubmed: 32563171
Epilepsy Res. 2019 Aug;154:34-38
pubmed: 31035242
Epilepsia. 2017 Apr;58(4):543-547
pubmed: 28166365
Epilepsy Behav. 2016 Sep;62:132-5
pubmed: 27459034
Epilepsy Behav Case Rep. 2015 Aug 08;4:48-51
pubmed: 26288756
Pediatr Int. 2019 Jun;61(6):611-613
pubmed: 31242539
Brain Dev. 2019 Oct;41(9):817-819
pubmed: 31122803
Epilepsia. 2019 Mar;60 Suppl 1:22-36
pubmed: 29953584
Rinsho Shinkeigaku. 2018 Oct 24;58(10):622-625
pubmed: 30270337
BMJ. 2020 Jan 16;368:l6890
pubmed: 31948937
Clin Neurophysiol. 2019 Oct;130(10):1804-1812
pubmed: 31401489